Over 50% of mice that were immunized with CT26 cell lysate grew tumors, which was substantially higher than mice immunized with intact TcdB-exposed tumor cells in which less than 10% of mice developed tumors (Figure 3B, p<0.0001). Here, DDX53 is linked to neoplasm.